BPC-157
Possibly the most-discussed research peptide online, and a near-perfect case study in the gap between a large animal literature and a human evidence base that hasn't caught up.
BPC-157 (Pentadecapeptide BPC 157)
Synthetic 15-amino-acid peptide
Tissue repair — tendon, ligament, muscle, gastrointestinal
Minimal — one retrospective study, two registered trials without reported efficacy results
No approval identified in the UK, EU, or US for any use
5 October 2026
BPC-157 is a synthetic peptide based on a partial sequence identified in human gastric juice — hence "BPC," short for "body protection compound." It isn't a naturally circulating hormone; it's a lab-synthesised fragment, studied since the early 1990s primarily by a research group led by Predrag Sikiric at the University of Zagreb.
Across a large body of rodent studies, BPC-157 has shown consistent effects on tissue healing — tendon-to-bone attachment, muscle injury, gut lining repair — which is unusual breadth for a single compound. That breadth, plus a proposed role in multiple overlapping repair pathways, is what's kept it a live research subject for over three decades, even without the compound ever reaching an approved product.
Proposed / preclinical mechanisms
Animal and cell studies propose effects on angiogenesis (new blood vessel growth), nitric oxide signalling, and upregulated growth hormone receptor expression in tendon fibroblasts — a broadly cytoprotective, pro-healing signalling profile.
What's actually established
None of this has been confirmed as the operating mechanism in human physiology. These are real, published preclinical findings — not yet validated human pharmacology.
Laboratory / In-vitro
Cell-culture studies on fibroblast activity and related signalling.
Animal / Preclinical
Extensive rodent literature since the early 1990s across tendon, ligament, muscle, bone, and GI healing.
Early Human Evidence
One retrospective study: intra-articular injection for knee pain.
Controlled Human Research
A 2015 Phase I safety trial never reported results; a 2026 Phase II trial for hamstring strain is recruiting, with no results yet.
Established Clinical Evidence
None identified for any indication.
- Population/model
- Literature review, 544 articles (1993–2024)
- Design
- Systematic review (PubMed/Cochrane/Embase)
- What researchers found
- Strong, consistent preclinical signal across models; only one clinical (human) study identified
- Major limitation
- Authors explicitly note no clinical safety data were found
- Population/model
- Rat, surgical Achilles detachment model
- Design
- Controlled animal study
- What researchers found
- Improved functional and biomechanical healing measures vs. controls
- Major limitation
- Animal model only — not evidence of a human effect
This is a representative sample, not an exhaustive list — chosen to show the actual shape of the evidence (strong preclinical, essentially absent controlled human data), not to cherry-pick a positive result.
Two registered human trials exist for BPC-157. Neither has reported efficacy results.
NCT02637284 (2015)
Phase I safety/pharmacokinetics trial, 42 healthy volunteers. Status unknown; no results were ever posted.
NCT07437547 (2026)
Phase II trial for acute hamstring strain. Currently recruiting — a registered trial, not a finding.
See both trials in the Clinical Trials Tracker → · Full detail on the hamstring trial →
"BPC-157 heals tendons, ligaments and the gut — it's clinically proven tissue repair."
A large, consistent preclinical (animal and cell) literature supporting tissue-repair mechanisms, plus one small retrospective human study and two registered trials without reported results.
A genuinely interesting, well-studied animal pharmacology. It does not support a "clinically proven" claim in humans — that evidence doesn't currently exist.
Whether, at what dose, by what route, and with what safety profile any of the animal-model effects translate to people.
Animal-heavy evidenceThe overwhelming majority of the literature is rodent-model, not human.
Single small human studyOne retrospective study is a starting point, not confirmation.
Missing published resultsA 2015 registered trial never reported results at all.
No replication in humansNo independent human trial has confirmed the animal findings.
No regulatory approval for BPC-157 has been identified in the UK, EU, or US, for any indication. It is not a licensed medicine anywhere. Read the full UK regulatory framework →
What We Still Don't Know
- Whether BPC-157's animal-model effects reproduce in human tissue at all.
- What dose, route, and duration would be relevant if they did.
- Its human safety profile — essentially unestablished by controlled trials.
- Whether the registered hamstring-strain trial will report a positive, negative, or null result.
Vasireddi N, et al., "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS Journal, 2025 (DOI 10.1177/15563316251355551). ClinicalTrials.gov records NCT02637284 and NCT07437547, verified directly via the official registry API. Preclinical tendon-healing literature as summarised in the above systematic review.
Evidence Library profile · Clinical Trials Tracker · Peptide Research, Explained